Investigating cancer evolution and biomarkers in EGFR-mutant lung cancer
Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC
This study is trying to understand how EGFR mutations affect lung cancer in patients and if certain genetic markers can help doctors make better treatment choices.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Locations | 1 site (Guanzhou) |
| Trial ID | NCT05997719 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the genomic architecture and cancer evolution in patients with EGFR-mutant non-small cell lung cancer (NSCLC). It will analyze the relationship between these factors and clinical outcomes, focusing on identifying prognostic and predictive biomarkers that could inform treatment decisions. The study will involve collecting tumor tissue samples from participants to assess their genomic characteristics and how these relate to patient prognosis. By understanding the distinct impacts of EGFR mutations on cancer evolution, the research seeks to improve clinical outcomes for this patient population.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with histologically or cytologically confirmed EGFR-mutant non-small cell lung cancer.
Not a fit: Patients with a history of other malignancies, insufficient tumor tissue for analysis, or unstable systemic diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better-targeted therapies and improved clinical outcomes for patients with EGFR-mutant NSCLC.
How similar studies have performed: Other studies have shown success in identifying biomarkers in EGFR-mutant NSCLC, suggesting that this approach is promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged 18 years or older 2. Histologically or cytologically confirmed non-small-cell lung cancer 3. ECOG PS=0-2 4. EGFR mutations confirmed by tissue or peripheral blood 5. Can provide tumor tissue samples (fresh or archived) 6. The subject should have good compliance, who would participate in the research voluntarily, and sign the informed consent Exclusion Criteria: 1. History of other malignancies within 5 years (excluding basal cell carcinoma of the skin or other carcinoma in situ that has been resected). 2. Unable to provide sufficient tumor tissue for analysis. 3. Subjects with active, unstable systemic diseases, such as active infection, uncontrolled hypertension, heart failure (NYHA class \>= II), unstable angina pectoris, acute coronary syndrome, severe arrythmia, severe liver, kidney or metabolic diseases, HIV infection. 4. Subjects who are deemed unable to comply with the study requirements or complete the study.
Where this trial is running
Guanzhou
- Sun Yat-sen University Cancer Center — Guanzhou, China (Recruiting)
Study contacts
- Study coordinator: Shen Zhao, MD.
- Email: zhaoshen@sysucc.org.cn
- Phone: 86 20 87343366
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.